News

Basel, Switzerland, July 30, 2010 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that first results from the TOCCATA observational study were presented at the 22nd Fortbildungswoche für praktische Dermatologie und Venerologie in Munich, Germany. TOCCATA was designed to investigate the clinical profile of Toctino® (alitretinoin) under daily practice conditions in severe chronic hand eczema (CHE) patients in Germany.

Basel, Switzerland, June 25, 2010 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announces that following a request for re-examination from the Applicant Janssen-Cilag International NV (Janssen-Cilag), a Johnson & Johnson company, the European Committee for Medicinal Products for Human Use (CHMP) confirmed its previous negative opinion on the Marketing Authorization Application (MAA) for ceftobiprole for the treatment of complicated skin and soft tissue infections (cSSTI).

Basel, Switzerland, June 25, 2010 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that its partner Astellas Pharma Inc. (TSE:4503) has initiated the formal process to allow continuation of patient recruitment into the phase III clinical studies of isavuconazole for the treatment of life-threatening invasive fungal infections. Certain study protocol amendments have been implemented and the phase III program will be expanded to include more patients.

Basel, Switzerland, June 15, 2010 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that Basilea Pharmaceutica International Ltd. has entered into an exclusive distribution agreement with Almirall, S.A. for Basilea's Toctino® (alitretinoin), a once-daily oral treatment for adults with severe chronic hand eczema unresponsive to potent topical corticosteroids, in selected European markets and Mexico.

Basel, Switzerland, May 18, 2010 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announces the inclusion of alitretinoin (Toctino®) in the guidelines and recommendations for the management of chronic hand eczema in Italy. The guidelines, published by the Italian Society of Dermatology (Società Italiana di Dermatologia medica, chirurgica, estetica e delle Malattie Sessualmente Trasmesse), recommend Toctino® as the treatment of choice when systemic treatment of severe chronic hand eczema is indicated.

Basel, Switzerland, May 03, 2010 - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the Italian Drug Agency (Agenzia Italiana del Farmaco [AIFA]).

Basel, Switzerland, April 28, 2010 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announces the integration of alitretinoin (Toctino®) for state-of-the-art management of chronic hand eczema in France. The position paper, recently published in the organ of the French Society of Dermatology (Société Française de Dermatologie), was elaborated by an expert panel and recommends Toctino® as the treatment of choice when clinical signs of chronic hand eczema persist under topical corticosteroids.

Basel, Switzerland, April 21, 2010 - New research data on Basilea's antitumor drug candidate BAL101553 (prodrug of BAL27862) was presented at the American Association of Cancer Research (AACR) Annual Meeting in Washington D.C. The novel, intravenous and orally bioavailable small molecule disrupts the intracellular microtubule network, a well established drug target in oncology. The data confirm that the compound elicits a unique microtubule phenotype and shows activity in a wide range of cancer types, including those resistant to current treatment options.

Basel, Switzerland, April 13, 2010 - Basilea Pharmaceutica Ltd. announces that new data on the antibacterial compounds BAL30072 and ceftobiprole as well as the antifungal drug isavuconazole were presented at the European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Vienna. Basilea's innovative and balanced anti-infective portfolio addresses priority concerns in the treatment of serious infections.

Basel, Switzerland, April 9, 2010 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announces that Janssen-Ortho Inc., a Johnson & Johnson company, has in consultation with Health Canada decided to discontinue sale of ceftobiprole (ZEFTERA(TM)) for the treatment of complicated skin and skin structure infections (cSSSI) in Canada.